Your browser doesn't support javascript.
loading
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.
Rejeski, Kai; Burchert, Andreas; Iacoboni, Gloria; Sesques, Pierre; Fransecky, Lars; Bücklein, Veit; Trenker, Corinna; Hernani, Rafael; Naumann, Ralph; Schäfer, Jonas; Blumenberg, Viktoria; Schmidt, Christian; Sohlbach, Kristina; von Bergwelt-Baildon, Michael; Bachy, Emmanuel; Barba, Pere; Subklewe, Marion.
Afiliação
  • Rejeski K; Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany.
  • Burchert A; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
  • Iacoboni G; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany.
  • Sesques P; Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
  • Fransecky L; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
  • Bücklein V; Department of Medicine, Universitat Autònoma of Barcelona (UAB), Bellaterra, Spain.
  • Trenker C; Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, Pierre-Bénite, France.
  • Hernani R; Medical Department II-Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Naumann R; Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany.
  • Schäfer J; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
  • Blumenberg V; Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
  • Schmidt C; Department of Hematology, Hospital Clínico Universitario, Institute for Research INCLIVA, Valencia, Spain; and.
  • Sohlbach K; Medical Department III-Hematology and Oncology, St. Marien-Krankenhaus Siegen, Siegen, Germany.
  • von Bergwelt-Baildon M; Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
  • Bachy E; Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany.
  • Barba P; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
  • Subklewe M; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany.
Blood Adv ; 6(16): 4719-4725, 2022 08 23.
Article em En | MEDLINE | ID: mdl-35793454
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Terapia de Salvação Idioma: En Revista: Blood Adv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Terapia de Salvação Idioma: En Revista: Blood Adv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha